RxDoctor Payments Data

Thomas Epperson, MD

Internal Medicine · Middlesboro, KYNPI 1184605966

Payments from drug & device makers

$2,183in general payments, 2019–2025

Across 159 payments — averaging $13.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$523
  • GSK$356
  • Amarin Pharma, Inc.$332
  • AstraZeneca$243
  • Pfizer$229
  • Lilly USA, LLC$182
  • plus $318 from 10 others

What the payments were for

  • Food & beverage$2,177100%
  • Education$60%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,183 in reported general payments places this provider in the 75th percentile of 1,284 internal medicine providers in Kentucky.

See all internal medicine providers in Kentucky

Medicare billing

Part B allowed, 2024
$13,238
Medicare patients
109
Services billed
246

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin221$124,017
EliquisApixaban330$120,924
FarxigaDapagliflozin Propanediol223$102,189
Trelegy ElliptaFluticasone/Umeclidin/Vilanter93$69,126
OzempicSemaglutide48$47,777
JanuviaSitagliptin Phosphate88$40,552
LinzessLinaclotide53$36,762
XareltoRivaroxaban41$17,604
EntrestoSacubitril/Valsartan31$17,442
VascepaIcosapent Ethyl40$12,729
Tresiba Flextouch U-100Insulin Degludec25$12,588
GemtesaVibegron44$11,955
MyrbetriqMirabegron18$11,079
DapagliflozinDapagliflozin Propanediol31$9,519
BrilintaTicagrelor41$9,227

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Abrysvo$229$127,136350 claims
Boehringer IngelheimJardiance$523$124,017221 claims
AstraZenecaFarxiga, Brilinta, Symbicort$243$117,207290 claims
GSKTrelegy Ellipta, Breo Ellipta, Shingrix$356$83,282140 claims
Novo NordiskOzempic, Levemir$74$50,61172 claims
AbbVieLinzess, Namzaric, Restasis$18$49,44897 claims
MerckJanuvia$40$40,55288 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,284 internal medicine providers in Kentucky.

Other internal medicine in Middlesboro

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →